Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rifampin + VCT220
- Development stage
- Unknown
- Lead developer
- CORXEL Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
rifampin + VCT220 is a drug combination utilized in Phase I clinical pharmacology studies to investigate drug-drug interactions (DDI). VCT220 (also known as CX11) is an investigational, orally bioavailable, small molecule agonist of the glucagon-like peptide-1 receptor (GLP-1R), developed by Vincentage Pharma for the treatment of obesity and type 2 diabetes. Rifampin is a macrocyclic antibiotic that acts as a potent inducer of cytochrome P450 enzymes (notably CYP3A4) and drug transporters such as P-glycoprotein (P-gp). The combination is specifically employed to evaluate the impact of metabolic induction on the pharmacokinetics, safety, and tolerability of VCT220 and its metabolite VCT289 in healthy volunteers. While VCT220 has progressed to Phase 3 registrational trials for obesity, this specific combination is used as a tool to characterize the drug's metabolic profile.
- Other names
- rifampicin + VCT220rifampin + CX11
02
Targets
ABCB1 (P-glycoprotein)CYP3A4 (Cytochrome P450 3A4)RNAP (Bacterial dna-dependent RNA polymerase)GLP1R (GLP-1R)
Beyond the preview
Go deeper on rifampin + VCT220.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rifampin + VCT220.